Abstract
ObjectiveDiffuse large B-cell lymphoma (DLBCL) is the most common histopathological type of non-Hodgkin’s lymphoma, which may arise from various extranodal sites. Little is known about the clinical characteristics and survival outcomes of primary DLBCL of the urinary tract (UT). Thus, we conducted this study to explore the independent prognostic factors of patients with UT-DLBCL using the Surveillance, Epidemiology, and End Results (SEER) database.Materials and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database for the data of patients diagnosed with UT-DLBCL between 1975 and 2016. Data, including demographic tumour stage and therapeutic strategies, such as surgical resection, radiation therapy, and chemotherapy, were collected. The impact of these factors on survival outcomes, including overall survival (OS) and disease-specific survival (DSS), was analysed using Kaplan–Meier curves.ResultsFour-hundred and eighty-nine patients who met the inclusion criteria were enrolled in the data analysis. The median age was 69 years old. Most cases of UT-DLBCL (72.39%) originated from the kidney, followed by the urinary bladder (24.95%). Both surgical resection and chemotherapy can significantly improve OS and DSS. Patients older than 75 years had the worst survival outcomes. Stage IV DLBCL may be a poor prognostic factor.ConclusionTo the best of our knowledge, this is the largest population-based study of UT-DLBCL. Advanced age, male gender, lack of surgical resection or chemotherapy, and stage IV DLBCL were poor prognostic factors.
Highlights
The most commonly diagnosed non-Hodgkin’s lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL), which accounts for approximately 30% of NHL cases [1]
This study explored the prognostic factors of patients with UT-DLBCL, based on data from the SEER database, to provide findings that will facilitate better clinic evaluations and more effective management of DLBCL
We enrolled 489 eligible patients diagnosed with UTDLBCL between 1975 and 2016 from the SEER database
Summary
The most commonly diagnosed non-Hodgkin’s lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL), which accounts for approximately 30% of NHL cases [1]. Lymphomas can arise in almost every organ or site, and approximately one-third of the patients have extranodal origins [2]. Less than 5% were genito-urinary lymphomas [3]. Lymphomas of the UT are extremely rare; no more than 100 cases have been reported so far Primary DLBCL of Urinary Tract globally [4]. The etiological exposure, clinical characteristics, and survival outcomes may vary for different sites of origin [5]. Increasing evidence has shown that extranodal sites demonstrate distinct clinical characteristics, survival outcomes, and require specific treatment [7, 8]. Studies on the clinical features and survival outcomes of DLBCL originating from the UT are limited
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
